HGSC patients exhibiting an immunoreactive profile trigger an immune response, which results in the recruitment of pro-angiogenic monocytes from the bone marrow, increased intratumoral hypoxia, upregulated HIF-1α, and a high pericyte coverage of the tumor vascular system. The gene discussed is HIF1A; the disease is neoplasm.